Sanofi says Genzyme won't hit first milestone in CVR deal

07/28/2011 | Reuters

Sanofi said it doesn't expect Genzyme to receive its first milestone fees under a contingent-value right agreement due to the company's inability to resume normal supply of Fabrazyme, one of its key drugs for rare diseases. "To return to normal supply levels of Fabrazyme for existing and new patients, the use of extra capacity at Genzyme's new manufacturing plant in Framingham, Mass., is required," the company announced.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health